NCT01301508

Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis

A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Bilateral Study of the Safety and Efficacy of Topically Applied AN2898 and AN2728 in the Treatment of Patients With Mild-to-Moderate Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 46 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether AN2898 and AN2728 ointments are safe and effective treatments for mild-to-moderate atopic dermatitis (AD).

Conditions

• Dermatitis, Atopic

Interventions

Type	Name	Description
DRUG	AN2728 ointment, 2%	AN2728 ointment, 2%, applied twice daily for 6 weeks
DRUG	AN2898 ointment, 1%	AN2898 ointment, 1%, applied twice daily for 6 weeks
DRUG	AN2898 ointment vehicle	AN2898 ointment vehicle applied twice daily for 6 weeks
DRUG	AN2728 ointment vehicle	AN2728 ointment vehicle applied twice daily for 6 weeks

Timeline

• Start date: 2011-05-01
• Primary completion: 2011-11-11
• Completion: 2011-11-11
• First posted: 2011-02-23
• Last updated: 2019-02-22
• Results posted: 2017-03-07

Locations

13 sites across 1 country: Australia